临床实践
Copyright ©The Author(s) 2018.
世界华人消化杂志. 2018-01-08; 26(1): 36-40
在线出版 2018-01-08. doi: 10.11569/wcjd.v26.i1.36
表2 两组患者治疗前后HCV DNA水平、肝功能改善及Child-Pugh评分的比较 (n = 20)
分组时间ALT (U/L)TBiL (μmol/L)Alc (g/L)Child-Pugh评分HCV DNA log10 (拷贝/mL)
观察组治疗前122.4 ± 25.248.1 ± 14.930.1 ± 3.011.0 ± 1.296.20 ± 1.02
治疗4 wk后111.9 ± 21.2a45.1 ± 15.1a30.0 ± 2.99.79 ± 2.55.20 ± 1.10
治疗12 wk后105.1 ± 17.9a40.9 ± 12.1a31.0 ± 1.9a10.3 ± 1.394.70 ± 1.47c
治疗24 wk后88.7 ± 17.9ac37.0 ± 10.1ac32.0 ± 2.0ac9.7 ± 1.109c3.73 ± 1.23c
治疗48 wk后48.1 ± 11.9ac30.0 ± 6.4ac35.2 ± 1.9ac7.4 ± 1.19ac3.32 ± 1.83c
对照组治疗前268.7 ± 43.071.0 ± 15.927.8 ± 1.4910.2 ± 1.36.43 ± 1.0
治疗4 wk后248.9 ± 31.9c67.0 ± 11.927.9 ± 2.49c10.79 ± 1.15.32 ± 4.01c
治疗12 wk后218.9 ± 36.160.0 ± 14.127.9 ± 2.010.2 ± 1.04.90 ± 1.30
治疗24 wk后177.1 ± 42.0c53.0 ± 14.1c29.1 ± 2.0c9.3 ± 1.2c4.40 ± 1.23c
治疗48 wk后106.3 ± 29.1c49.4 ± 18.2c31.2 ± 1.8c8.4 ± 1.2c3.79 ± 1.01c

引文著录: 柴健, 韦学明, 张洁. 阿德福韦酯联合拉米夫定对乙型肝炎肝硬化失代偿期抗病毒效应的疗效对比. 世界华人消化杂志 2018; 26(1): 36-40